Finance

Lists
Why is XERS up 2.85%?
Dive Deeper
XERS:NASDAQ
Xeris Biopharma Holdings Inc
$10.48
+2.85%
(+0.29) 1D
$10.48
0.00% (0.00)
After hours
Closed: Oct 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XERS...
Open
$10.15
High
$10.60
Low
$10.07
Mkt. cap
1.91B
Avg. vol.
2.79M
Volume
3.00M
52-wk high
$11.33
52-wk low
$5.25
EPS
-$0.11
Beta
0.68
Shares outstanding
182.32M
No. of employees
435
Open
$10.15
High
$10.60
Low
$10.07
Mkt. cap
1.91B
Avg. vol.
2.79M
Volume
3.00M
52-wk high
$11.33
52-wk low
$5.25
EPS
-$0.11
Beta
0.68
Shares outstanding
182.32M
No. of employees
435
News stories
From web sources and news partners
About Xeris Biopharma Holdings Inc
CEO-
Employees435
Founded2005
HeadquartersChicago, Illinois, United States
SectorPharmaceutical industry
Websitexerispharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to XERS in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for XERS in the last 3 months.
Highest
Current $10.48
$18.00 (+71.76%)
Average
$13.00 (+24.05%)
Lowest
$8.00 (-23.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jenna Davidner
Barclays
Buy
Maintained
$14.00
+33.6%
10/06/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
$12.00
+14.5%
09/29/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$10.00
-4.6%
09/21/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$18.00
+71.8%
09/10/2026
David Amsellem
Piper Sandler
Hold
Reiterated
$8.00
-23.7%
09/10/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
$16.00
+52.7%
09/10/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
-$0.00 / $0.00
-172.00%miss
Revenue / Est. (USD)
92.10M / 90.12M
+2.19%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
74.38M
85.81M
83.13M
92.10M
Cost of goods sold
11.00M
10.95M
10.57M
12.51M
Cost of revenue
11.00M
10.95M
10.57M
12.51M
Research and development expenses
7.48M
7.87M
8.78M
10.67M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46.46M
47.50M
53.14M
61.04M
Operating expense
56.65M
58.09M
64.64M
74.42M
Total operating expenses
67.65M
69.03M
75.21M
86.93M
Operating income
6.73M
16.77M
7.92M
5.17M
Other non operating income
-
-
-
-
EBT including unusual items
621.00K
11.08M
2.23M
-31.10M
EBT excluding unusual items
621.00K
11.08M
2.23M
-319.00K
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
621.00K
11.08M
2.23M
-31.10M
Net profit margin
0.83%
12.91%
2.69%
-33.77%
Earnings per share
-
0.06
0.01
-0.00
Interest and investment income
1.16M
1.46M
1.20M
1.46M
Interest expense
-7.27M
-7.15M
-6.88M
-6.95M
Net interest expenses
-6.11M
-5.69M
-5.68M
-5.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
9.78M
19.82M
10.96M
8.21M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps